Published in Circ Res on March 03, 2017
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell (2014) 5.43
In vivo genome editing using Staphylococcus aureus Cas9. Nature (2015) 5.26
Regulation of homologous recombination in eukaryotes. Annu Rev Genet (2010) 4.33
Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell (2014) 3.16
A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet (2015) 2.84
Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature (2014) 2.33
Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging. Circ Res (2012) 1.84
Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J (2015) 1.31
The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. Nat Genet (2016) 1.24
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol (2016) 1.10
Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. EMBO Mol Med (2013) 1.01
Hurdles to clinical translation of human induced pluripotent stem cells. J Clin Invest (2015) 0.98
Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy. EMBO Mol Med (2015) 0.93
Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. Physiol Rev (2016) 0.92
Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies. Adv Drug Deliv Rev (2015) 0.91
Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review. JAMA Cardiol (2016) 0.86
Duchenne muscular dystrophy: CRISPR/Cas9 treatment. Cell Res (2016) 0.79